Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $23.54M
• Dividend Yield: N/A
• Average Volume (3M): 3.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 88.13%
• EPS Growth: 92.45%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 8,850,386
• 10 Day Avg. Volume: 8,961,395
• 30 Day Avg. Volume: 3,012,994
• PEG Ratio: -0.23
• Price to Book (P/B): -2.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.88
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 3.89
• Enterprise Value/Gross Profit: -1.29
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $12.00
• Price Target Upside: 351.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $2.50 ▼(-6.02%Downside)

Daré Bioscience's overall stock score is primarily impacted by its challenging financial situation, including negative equity and ongoing losses. However, positive developments in clinical trials and strategic initiatives offer a glimpse of potential future improvement.

Positive Factors

Product Development

Positive interim results from the P3 study of Ovaprene show a pregnancy rate in line with or better than current contraceptive methods.

Strategic Partnerships

If Bayer exercises its commercial option for Ovaprene, Dare would earn another $20M milestone, strengthening the company's balance sheet.

Negative Factors

Financial Needs

Additional capital will likely be needed, and potentially significantly dilutive, to fund Daré's programs.

Study Enrollment

Enrollment in the study was negatively affected by NIH cuts, causing recruitment at NIH CCTN sites to pause.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience (DARE) is a biopharmaceutical company focusing on the development and commercialization of innovative products in women's health. The company's portfolio includes a range of clinical-stage candidates designed to address unmet needs in contraception, fertility, and sexual health. Daré Bioscience aims to enhance the quality of life for women by developing products that offer novel or improved therapeutic options across these key areas.

How the Company Makes Money

Daré Bioscience makes money primarily through the development and commercialization of its proprietary women's health products. The company generates revenue by partnering with pharmaceutical companies for the commercialization and distribution of its products once approved by regulatory authorities. These partnerships often include upfront payments, milestone payments based on the achievement of development and regulatory milestones, and royalties from product sales. Daré Bioscience's earnings are also supported by government grants and research collaborations that help fund the development of its clinical pipeline.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges, with persistent unprofitability, negative equity, and high liabilities indicating financial distress. Despite a recent positive trend in cash flow and revenue growth, the company's long-term sustainability remains questionable without a turnaround in profitability and a more stable balance sheet.

Income Statement

Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.

Balance Sheet

The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.

Cash Flow

While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.78K	2.81M	10.00M	0.00	0.00
Gross Profit	-14.29M	2.77M	9.95M	-26.41K	-43.23K
EBITDA	-23.41M	-30.90M	-31.36M	-39.04M	-27.36M
Net Income	-4.05M	-30.16M	-30.95M	-38.33M	-27.40M
Balance Sheet
Total Assets	22.10M	21.28M	43.83M	55.81M	7.55M
Cash, Cash Equivalents and Short-Term Investments	15.70M	10.48M	34.67M	51.67M	4.67M
Total Debt	1.30M	1.40M	488.74K	270.55K	756.84K
Total Liabilities	28.11M	26.33M	32.71M	17.05M	8.70M
Stockholders Equity	-6.01B	-5.05M	11.11M	38.75M	-1.15M
Cash Flow
Free Cash Flow	4.82M	-39.49M	-18.15M	-28.78M	-25.25M
Operating Cash Flow	5.39M	-38.86M	-18.09M	-28.76M	-25.23M
Investing Cash Flow	-573.05K	-629.43K	-63.07K	-14.52K	-17.63K
Financing Cash Flow	433.83K	15.64M	1.34M	75.85M	25.13M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Neutral. The current price of 2.66 is above the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.79, and below the 200-day MA of 3.12, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 7.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$16.84B	5.17	-7.44%	2.89%	11.55%	-28.15%
CLNN	50 Neutral	$33.60M	―	-1738.36%	―	-43.55%	69.81%
DARE	50 Neutral	$23.54M	―	597.53%	―	88.13%	92.45%
VYNE	48 Neutral	$24.16M	―	-66.15%	―	43.03%	81.75%
GBIO	46 Neutral	$29.03M	―	-70.06%	―	146.47%	57.85%
PYPD	41 Neutral	$38.32M	―	-853.05%	―	―	34.97%
NRSN	30 Underperform	$49.18M	―	-2880.11%	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience Announces Positive Phase 3 Trial Results

On July 14, 2025, Daré Bioscience announced positive interim results from its Phase 3 clinical trial of Ovaprene®, a hormone-free monthly intravaginal contraceptive. The trial’s data safety monitoring board recommended continuing the study without modification, as no new safety concerns were identified. Approximately 9% of participants experienced pregnancy, aligning with expectations, while 17% discontinued due to vaginal odor. Participants expressed a high likelihood of using Ovaprene if available, highlighting its potential to meet the demand for hormone-free contraceptive options. Bayer has the option to commercialize Ovaprene in the U.S., potentially providing significant financial benefits to Daré.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience Stockholder Meeting Approves Key Proposals

On July 9, 2025, Daré Bioscience reconvened its stockholder meeting initially held on June 12, 2025, which was adjourned due to a lack of quorum. During the meeting, four proposals were voted on, including the election of Class II directors, the ratification of Haskell & White LLP as the independent accounting firm for 2025, approval of executive compensation, and the 2022 Plan Amendment, all of which were passed by the stockholders.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience Gains Nasdaq Compliance Extension Approval

On June 24, 2025, Daré Bioscience received approval from the Nasdaq Hearings Panel for its modified plan to regain compliance with Nasdaq Listing Rules, with a conditional continued listing period until August 12, 2025. The company must demonstrate compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule by July 31, 2025, or face potential delisting, which could impact its stock market presence and capital-raising capabilities.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience Announces Corporate Presentation for Investors

On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.

The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.